
CLAIMS

1. A conjugate of formula I:

$$L - (D^L)_p \qquad (I)$$

wherein L is a Ligand unit, D is a Drug Linker unit of formula II:




(II)

wherein

either:

(a) R^{10} and R^{11} form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or


(b) R^{10} is OH, and R^{11} is:



;


p is an integer of from 1 to 20.

2. A conjugate according to claim 1, wherein D^L is D^L-A:



.

3. A conjugate according to claim 1, wherein D^L is D^L-B:



4. A conjugate according to any one of claims 1 to 3, wherein the Ligand Unit is an antibody or an active fragment thereof.

5. The conjugate according to claim 4, wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen.

6. The conjugate according to claim 4 wherein the antibody or antibody fragment is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(88):

(1) BMPR1B;
(2) E16;
(3) STEAP1;
(4) 0772P;
(5) MPF;
(6) Napi3b;
(7) Sema 5b;
(8) PSCA hlg;
(9) ETBR;
(10) MSG783;
(11) STEAP2;
(12) TrpM4;
(13) CRIPTO;
(14) CD21;
(15) CD79b;
(16) FcRH2;
(17) HER2;
(18) NCA;

(19) MDP;

(20) IL20R-alpha;

(21) Brevican;

(22) EphB2R;

(23) ASLG659;

(24) PSCA;

(25) GEDA;

(26) BAFF-R;

(27) CD22;

(28) CD79a;

(29) CXCR5;

(30) HLA-DOB;

(31) P2X5;

(32) CD72;

(33) LY64;

(34) FcRH1;

(35) IRTA2;

(36) TENB2;

(37) PSMA – FOLH1;

(38) SST;

(38.1) SSTR2;

(38.2) SSTR5;

(38.3) SSTR1;

(38.4)SSTR3;

(38.5) SSTR4;

(39) ITGAV;

(40) ITGB6;

(41) CEACAM5;

(42) MET;

(43) MUC1;

(44) CA9;

(45) EGFRvIII;

(46) CD33;

(47) CD19;

(48) IL2RA;

(49) AXL;

(50) CD30 - TNFRSF8;

(51) BCMA - TNFRSF17;

(52) CT Ags – CTA;

(53) CD174 (Lewis Y) - FUT3;

(54) CLEC14A;

(55) GRP78 – HSPA5;

(56) CD70;

(57) Stem Cell specific antigens;

(58) ASG-5;

(59) ENPP3;

(60) PRR4;

(61) GCC – GUCY2C;

(62) Liv-1 – SLC39A6;

(63) 5T4;

(64) CD56 – NCMA1;

(65) CanAg;

(66) FOLR1;

(67) GPNMB;

(68) TIM-1 – HAVCR1;

(69) RG-1/Prostate tumor target Mindin – Mindin/RG-1;

(70) B7-H4 – VTCN1;

(71) PTK7;

(72) CD37;

(73) CD138 – SDC1;

(74) CD74;

(75) Claudins – CLs;

(76) EGFR;

(77) Her3;

(78) RON - MST1R;

(79) EPHA2;

(80) CD20 – MS4A1;

(81) Tenascin C – TNC;

(82) FAP;

(83) DKK-1;

(84) CD52;

(85) CS1 - SLAMF7;

(86) Endoglin – ENG;

(87) Annexin A1 – ANXA1;
(88) V-CAM (CD106) - VCAM1.

7. The conjugate according to any one of claims 4 to 6 wherein the antibody or antibody fragment is a cysteine-engineered antibody.

8. The conjugate according to any one of claims 1 to 7 wherein p is an integer from 1 to 8.

9. The conjugate according to claim 8, wherein p is 1, 2, 3, or 4.

10. A composition comprising a mixture of conjugates according to any one of claims 1 to 9, wherein the average p in the mixture of conjugate compounds is about 1 to about 8.

11. The conjugate according to any one of claims 1 to 9, for use in therapy.

12. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 9 and a pharmaceutically acceptable diluent, carrier or excipient.


13. The conjugate according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 12, for use in the treatment of a proliferative disease in a subject.

14. The conjugate for use according to claim 13, wherein the disease treated is cancer.

15. Use of a conjugate according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of a proliferative disease.

16. The use according to claim 15, wherein the proliferative disease is a cancer.

17. A compound of formula III:




(III)

wherein

either:


(a) R^{10} and R^{11} form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or

(b) R^{10} is OH, and R^{11} is:




.

18. A compound according to claim 17 which is A:



.

19. A compound according to claim 17 which is B:



.

20. A method of synthesis of a conjugate according to any one of claims 1 to 9 comprising the step of conjugating a compound according to any one of claims 17 to 19 with a cell-binding agent.